Helio Genomics has announced a strategic commercial partnership with Syneos Health to accelerate nationwide adoption of HelioLiver, its AI-powered blood test for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. The collaboration draws on Syneos Health’s commercialization expertise, national field deployment, and experience engaging healthcare providers to build awareness and drive adoption of the test across the United States.
HelioLiver is designed to fit into routine liver cancer surveillance with a simple blood draw. By combining cell-free DNA methylation patterns, protein biomarkers, and patient demographics through proprietary AI algorithms, it provides an additional early signal of risk and disease, even when ultrasound findings are inconclusive. In the CLiMB trial, which enrolled nearly 1,968 patients across roughly 50 clinical sites, HelioLiver showed four times greater sensitivity for Stage I liver cancer than ultrasound and surpassed all FDA-specified endpoints. The test is reimbursed by Medicare at $662 per test (CPT 0333U).
“Partnering with Syneos Health represents a major leap forward in our commercialization strategy and de-risks the path to broad market adoption of HelioLiver,” said Dr. Bharat Tewarie, CEO of Helio Genomics, adding that Syneos will accelerate provider engagement across the country. Paul Mignon, President and Global Head of Deployment Solutions at Syneos Health, said the collaboration reflects a commitment to helping innovators translate scientific advances into commercial success while expanding patient access. Syneos will deliver targeted field engagement, tailored education and integrated promotion to reach hepatologists, gastroenterologists and other providers, supported by its AI-powered Kinetic platform. The partnership also builds on Helio’s recent agreement with Quest Diagnostics, which provides access to more than 7,700 patient service centers and over 900 EHR systems nationwide.
The need is urgent. Liver cancer is emerging as a silent epidemic in the United States, often undetected until advanced stages, with incidence tripling and mortality doubling since 1980. Yet when the disease is caught early, the five-year survival rate rises to about 70 percent, and current AASLD guidelines recommend surveillance every six months for high-risk patients such as those with cirrhosis or hepatitis B. Because an estimated 80 to 90 percent of eligible adults skip recommended ultrasounds, a simple blood-based test like HelioLiver, now commercially available nationwide, aims to close that gap and support earlier, more effective treatment.
View source version on prnewswire.com.